In summary, these findings suggest that the live α-PA vaccine described herein could be a promising approach to achieve mucosal immunity against pneumonia caused by highly pathogenic PA strains and possibly those that are refractory to broad-spectrum antibiotics. This evidence concerns the gene ENPEP and pneumonia.